A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 297-304

  Sharma, S ^a   Abhyankar, V ^b   Burgess, R E ^b   Infante, J ^c   Trowbridge, R C ^d   Tarazi, J ^e   Kim, S ^e   Tortorici, M ^e   Chen, Y ^e   Robles, R L ^f  

^a NEVADA CANCER INSTITUTE   (United States)

^b East Carolina School of Dental Medicine   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d St Francis Healthcare Centers   (United States)

^e PFIZER INC   (United States)

^f Bay Area Cancer Research Group   (United States)

Author keywords

Axitinib; Bevacizumab; Colorectal cancer; FOLFIRI; FOLFOX

Indexed keywords

AXITINIB; BEVACIZUMAB; FIRTECAN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FOLFOX PROTOCOL; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; ADENOCARCINOMA; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; IMIDAZOLES; INDAZOLES; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 77951907727     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp489     Document Type: Article

References (28)

1. Hurwitz H. New combinations in metastatic colorectal cancer: what are our expectations? Oncologist 2005; 10: 320-322.
2. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
3. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
4. Hu-Lowe DD, Zou HY, Grazzini ML et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008; 14: 7272-7283.
5. Cohen E, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histological subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008; 26: 4708-4713.
6. Schiller JH, Larson T, Ou SI et al. Efficacy and safety of axitinib in patients with advanced non-small cell lung cancer: results from a phase II study. J Clin Oncol 2009; 27: 3836-3841.
7. Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8: 975-984.
8. Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 4462-4468.
9. Rugo HS, Stopeck A, Joy AA et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). J Clin Oncol 2007; 25(18S): 32s (Abstr).
10. Spano JP, Chodkiewicz C, Maurel J et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008; 371: 2101-2108.
11. Cao Y, Tan A, Gao F et al. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 2009; 24: 677-685.
12. Hu-Lowe D, Grazzini M, Amundson K et al. Antiangiogenic inhibitor axitinib (AG-013736) renders significant growth inhibition of bevacizumab-refractory xenograft tumors. Eur J Cancer Suppl 2006; 4(12): 25 (Abstr).
13. Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23: 5474-5483.
14. Liu G, Rugo HS, Wilding G et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23: 5464-5473.
15. de Gramont A, Tournigand C, Louvet C et al. [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD]. Rev Med Interne 1997; 18: 769-775.
16. Andre T, Louvet C, Maindrault-Goebel F et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35: 1343-1347.
17. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
18. AVASTIN®. (Bevacizumab) Prescribing Information. San Francisco, CA: Genentech Inc. 2009.
19. Cooney MM, Garcia JA, Elson P et al. Sunitinib and bevacizumab in advanced solid tumors: a phase I trial. J Clin Oncol 2008; 26(15S): 160s (Abstr).
20. Garcia JA, Cooney MM, Mekhail T et al. Sunitinib and bevacizumab in advanced solid tumors: preliminary results of a phase I trial. J Clin Oncol 2008; 26(15S): 3530s (Abstr).
21. Feldman DR, Ginsberg MS, Baum M et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26(15S): 274s (Abstr).
22. Sosman JA, Flaherty KT, Atkins MB et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008; 26(15S): 252s (Abstr).
23. Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26: 3709-3714.
24. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11: 81-88.
25. Graham MA, Lockwood GF, Greenslade D et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000; 6: 1205-1218.
26. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-237.
27. Gupta E, Lestingi TM, Mick R et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-3725.
28. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005; 106: 97-132.